Loading
NASDAQHealthcareBiotechnology
Latest quote
$39.86
−$0.11 · -0.28%
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Previous close
$39.86
−$0.11 · -0.28%
Regular session · ET · Market data may be delayed.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Day range
Current $39.86
52-week range
Current $39.86
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
62
Undervalued
Sentiment
64
Bullish
Risk
37
Moderate Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Day range
Current $39.86
52-week range
Current $39.86
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$57.00
43.00% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI105.77M0.00%2.3T USD0.03%$379.73-0.32%
State Street SPDR S&P Biotech ETFXBI98.37M0.86%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM85.53M0.11%80.51B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF38.2M0.04%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN28.26M0.19%14.61B USD0.24%$224.62+0.40%
iShares Biotechnology ETFIBB25.06M0.23%10.73B USD0.44%$211.92-0.88%
Schwab U.S. Small-Cap ETFSCHA17.76M0.08%22.93B USD0.03%$34.55+1.01%
Vanguard Russell 2000 ETFVTWO16.71M0.09%17.4B USD0.06%$119.62+0.25%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.